Finotti Michele, Romano Maurizio, Auricchio Pasquale, Scopelliti Michele, Brizzolari Marco, Grossi Ugo, Piccino Marco, Benvenuti Stefano, Morana Giovanni, Cillo Umberto, Zanus Giacomo
4th Surgery Unit, Regional Hospital Treviso, DISCOG, University of Padua, 31100 Padua, Italy.
Hepatobiliary Surgery and Liver Transplantation Unit, DISCOG, University of Padua, 35121 Padua, Italy.
J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.
Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.
近年来，非酒精性脂肪性肝病已成为慢性肝病日益常见的病因。这种疾病通常发生在患有多种合并症的患者身上，即所谓的代谢综合征。治疗选择多种多样，从生活方式改变、药物治疗到特定病例的肝移植。选择最有益的治疗方法及其相互作用可能具有挑战性。必须根据疾病的严重程度对患者进行分层，以便调整可用的治疗方法。在我们的文章中，我们回顾了最新的药物靶向治疗、减肥手术的作用以及肝移植对非酒精性脂肪性肝病预后的影响。
